Insights from Chris Mycek, Head of Commercialization at Benchworks, a Danforth Health Company 

Launching in an ultra-rare disease market is not a volume game. Success depends on whether the right physicians have the confidence, clarity, and support to identify patients, initiate treatment, and continue prescribing. 

That is what makes healthcare professional (HCP) engagement so critical. 

In broader specialty markets, commercial teams can often rely on scale and repetition to build awareness and drive adoption. In ultra-rare disease, the equation is different. Prescriber universes are small, treatment decisions are highly nuanced, and each account can materially influence launch performance. When uptake falls short, the issue is often not awareness alone. More often, it is a gap in confidence, coordination, or capability. 

A recent case study involving the launch of a first-in-class therapy for a rare pediatric metabolic disorder highlights this dynamic. 

When Awareness is Not Enough 

A mid-sized biotechnology company launched a therapy for a rare pediatric metabolic disorder affecting roughly 2,000 patients in the United States. The product entered the market with strong Phase 3 efficacy data and favorable payer coverage. On paper, the launch appeared well-positioned. 

Yet in the first 18 months, revenue significantly underperformed projections. 

Commercial analysis showed the company had correctly identified its core prescriber base: approximately 85 pediatric metabolic specialists. But actual prescribing was concentrated among just 22 of them. 

The remaining specialists were aware of the therapy but hesitant to act. Their concerns centered on patient selection, timing of treatment initiation, comfort with the novel mechanism of action, potential long-term safety considerations, and uncertainty around insurance coverage and out-of-pocket costs. Some also viewed the therapy as relevant only for the most severe phenotypes rather than the broader eligible population. 

This pattern is common in ultra-rare disease.  

Awareness may open the door, but it rarely drives adoption on its own. In highly specialized markets, prescribing decisions require deeper clinical confidence, practical support, and coordinated engagement across functions. 

A More Targeted Intervention 

Working with Benchworks, a Danforth Health Company, the organization implemented a six-month HCP engagement program focused on sharper targeting and stronger field coordination.  

The strategy our experts facilitated centered on five key moves. 

1. Refining segmentation beyond simple prescriber lists 

The team developed a more dynamic targeting model based on patient volume, growth potential, and alignment with treatment philosophy. In ultra-rare disease, effective segmentation must go beyond static prescriber lists to identify the accounts most likely to drive near-term adoption. 

2. Enabling peer-to-peer learning 

The company launched small-group dinners and virtual roundtables featuring active prescribers sharing real-world clinical experience. This peer-to-peer model helped move physicians from awareness to greater confidence in patient selection and treatment initiation. 

3. Tightening MSL and field integration 

Weekly account planning sessions improved coordination between MSLs and field teams, enabling more aligned and responsive engagement. In ultra-rare disease, seamless medical-commercial collaboration is essential to delivering credible, timely support. 

4. Addressing access concerns directly 

The company developed payer-specific guidance and hub services talking points to address coverage and affordability questions. Clear access communication helped reduce friction between prescription intent and therapy start. 

5. Supporting treatment initiation with practical tools 

The launch team created clinical support materials, including dosing algorithms, monitoring protocols, and adverse event guidance. These resources helped physicians feel more prepared to initiate treatment with confidence. 

The Impact of Coordinated HCP Engagement 

Within six months of engagement with our experts, the company saw meaningful improvement across key launch metrics: 

• Active prescribers increased from 22 to 58  

• New patient starts rose 47% quarter over quarter  

• Prescription abandonment fell from 23% to 11%  

• Time from first prescription to second prescription dropped from 8.3 months to 4.7 months  

• Net revenue increased 12% year over year despite flat pricing  

The takeaway is clear: when commercial teams address the specific barriers holding physicians back, adoption can accelerate meaningfully even in a small, highly specialized market. 

Looking to Strengthen Launch Performance? 

From launch planning to HCP engagement strategy, Danforth Health’s commercial readiness experts help life sciences companies build smarter launch strategies, align cross-functional teams, and accelerate adoption in complex markets. 

Reach out to our team today.